Rheumatoid arthritis (RA) is an autoimmune disorder characterized by chronic inflammation leading to joint damage, with treatment aimed at reducing inflammation.
Traditional medications may have non-specific effects on cell metabolism, prompting interest in specialized pro-resolving mediators (SPMs), which help resolve inflammation and restore tissue health.
SPMs are derived from omega-3 fatty acids and their production may be disrupted in RA, highlighting their potential as protective and healing agents in managing the condition.